Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10725828 | 0.79 | HTT (0.53) | HTTMEN1KMT2AHRH3CYP2A13 | |
| SCHEMBL5256185 | 0.77 | HTT (0.54) | MAPTHTTMEN1KMT2AHRH3 | |
| SCHEMBL14080631 | 0.76 | HTT (0.50) | HTTMEN1KMT2AHRH3CYP2A13 | |
| SCHEMBL14235132 | 0.76 | HTT (0.50) | HTTMEN1KMT2AHRH3CYP2A13 | |
| SCHEMBL5253784 | 0.76 | HTT (0.53) | HTTMEN1KMT2AHRH3CYP2A13 | |
| SCHEMBL16182099 | 0.76 | HTT (0.53) | HTTMEN1KMT2AHRH3CYP2A13 | |
| SCHEMBL14213300 | 0.75 | HTT (0.49) | HTTMEN1KMT2AHRH3CYP2A13 | |
| SCHEMBL4111089 | 0.71 | CYP2A13 (0.63) | MAPTMEN1KMT2ACYP2A13ALDH1A1 | |
| SCHEMBL5108673 | 0.70 | GABRA1 (0.43) | ALDH1A1 | |
| SCHEMBL14132172 | 0.70 | HTT (0.46) | HTTMEN1KMT2AHRH3CYP2A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309750-A1 | 5-MEMBERED HETEROCYCLE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | ILDONG PHARM CO., LTD. (KR) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309750-A1 | 5-MEMBERED HETEROCYCLE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | CYP3A5, UGT2B7, UGT1A7 | MAPT 64/4885HTT 1176/4885MEN1 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.